NASDAQ:AMYT Amryt Pharma (AMYT) Stock Price, News & Analysis → Crypto Market Preps For Trillions Worth of Inflows! (From Crypto 101 Media) (Ad) Free AMYT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$14.63▼$14.7650-Day Range$14.55▼$14.7052-Week Range$6.41▼$14.77Volume2.39 million shsAverage Volume757,360 shsMarket Capitalization$940.21 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Amryt Pharma alerts: Email Address Ad WealthPressA lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. Click here to jump in on the next one About Amryt Pharma Stock (NASDAQ:AMYT)Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.Read More Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. AMYT Stock News HeadlinesOctober 13, 2023 | wsj.comAlembic Pharmaceuticals Ltd.October 10, 2023 | investing.comAMYT Historical DataMarch 29, 2024 | Crypto 101 Media (Ad)Crypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.July 28, 2023 | wsj.comBeijing Sun-Novo Pharmaceutical Research Co. Ltd. AApril 11, 2023 | finance.yahoo.com2022 for Chiesi: The Group’s international growth continuesApril 3, 2023 | finance.yahoo.comHigh Court of Justice of England and Wales Sanctions Scheme of ArrangementMarch 17, 2023 | benzinga.comAmryt Pharma Stock (NASDAQ:AMYT), DividendsFebruary 16, 2023 | finance.yahoo.comAMRYT PUBLISHES SCHEME CIRCULAR AND ANNOUNCES THE SHAREHOLDER MEETINGS TO CONSIDER AND VOTE ON THE CHIESI ACQUISITION WILL BE HELD ON MARCH 22, 2023March 29, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…January 9, 2023 | msn.comWhy CinCor Pharma Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving PremarketJanuary 9, 2023 | msn.comEuropean drugmakers including AstraZeneca pony up for U.S.-listed biopharmasJanuary 6, 2023 | markets.businessinsider.comMaxim Group Reaffirms Their Buy Rating on Amryt Pharma (AMYT)January 5, 2023 | finance.yahoo.comAmryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFHNovember 7, 2022 | markets.businessinsider.comSVB Securities Keeps Their Buy Rating on Amryt Pharma (AMYT)November 6, 2022 | seekingalpha.comAmryt Pharma PLC (AMYT) Q3 2022 Earnings Call TranscriptNovember 3, 2022 | finance.yahoo.comAmryt Reports Q3 2022 Financial and Operational ResultsOctober 31, 2022 | msn.comLigand Pharmaceuticals (LGND) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseOctober 27, 2022 | finance.yahoo.comAmryt Pharma PLC Sponsored ADR (AMYT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseOctober 25, 2022 | finance.yahoo.comThe British Journal of Dermatology Publishes Results from Amryt’s EASE Phase 3 Trial in Epidermolysis BullosaOctober 24, 2022 | finance.yahoo.comAmryt Supports Global EB Awareness Week 2022October 19, 2022 | finance.yahoo.comAmryt to Report Q3 2022 Results on November 3, 2022September 23, 2022 | finance.yahoo.comAmryt Supports FH Awareness Day – September 24, 2022September 16, 2022 | marketwatch.comAmryt Pharma Gets CHMP Backing for Mycapssa in Acromegaly >AMYTSeptember 16, 2022 | finance.yahoo.comCHMP adopts positive opinion for Mycapssa® for the treatment of AcromegalySeptember 8, 2022 | msn.comAmryt Secures UK Regulatory Nod And Orphan Disease Status For Skin Disorder CandidateSeptember 8, 2022 | finance.yahoo.comAmryt Receives Marketing Authorisation Approval and Orphan Drug Designation for Filsuvez® in Great BritainSeptember 7, 2022 | finance.yahoo.comAmryt to Present Data from MPOWERED Phase 3 Trial of Mycapssa® (oral octreotide) at ENEA 2022See More Headlines Receive AMYT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amryt Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/05/2020Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AMYT CUSIPN/A CIK1783010 Webwww.amrytpharma.com Phone353-1518-0200FaxN/AEmployees2,020Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$1 million Net Margins-8.19% Pretax Margin-0.56% Return on Equity1.70% Return on Assets0.75% Debt Debt-to-Equity Ratio0.64 Current Ratio1.57 Quick Ratio0.94 Sales & Book Value Annual Sales$222.54 million Price / Sales4.22 Cash Flow$0.98 per share Price / Cash Flow14.98 Book Value$5.58 per share Price / Book2.63Miscellaneous Outstanding Shares63,960,000Free Float60,343,000Market Cap$940.21 million OptionableNot Optionable Beta0.84 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Joseph A. Wiley (Age 51)CEO & Director Comp: $1.65MMr. Rory P. Nealon (Age 54)CFO, COO & Company Sec. Comp: $890kMs. Elizabeth Varki Jobes J.D. (Age 55)Chief Compliance Officer Mr. John McEvoyGen. CounselMr. Stephen JoyceHead of Marketing & Head of APACMs. Julie EastwoodHead of HRDr. Helen PhillipsHead of Medical AffairsMs. Sheila M. Frame (Age 60)Pres of Americas Dr. Tracy CunninghamChief Medical OfficerMr. Jordi CasalsPres of EMEA RegionMore ExecutivesKey CompetitorsABIVAX Société AnonymeNASDAQ:ABVXInnovivaNASDAQ:INVAARS PharmaceuticalsNASDAQ:SPRYORIC PharmaceuticalsNASDAQ:ORICArcutis BiotherapeuticsNASDAQ:ARQTView All Competitors AMYT Stock Analysis - Frequently Asked Questions How were Amryt Pharma's earnings last quarter? Amryt Pharma plc (NASDAQ:AMYT) released its earnings results on Thursday, November, 5th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.66. The company earned $49.33 million during the quarter. Amryt Pharma had a negative net margin of 8.19% and a positive trailing twelve-month return on equity of 1.70%. What other stocks do shareholders of Amryt Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amryt Pharma investors own include Immunic (IMUX), Chimerix (CMRX), Livongo Health (LVGO), Otonomy (OTIC), Akero Therapeutics (AKRO), Albireo Pharma (ALBO), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD) and Applied DNA Sciences (APDN). This page (NASDAQ:AMYT) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryOnly a fool would buy Nvidia today… Porter & CompanyAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amryt Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.